# Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

> **NCT02959970** · PHASE4 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 100 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** dapsone gel

## Key facts

- **NCT ID:** NCT02959970
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-31
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-03-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959970, "Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02959970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*